Inventor · disambiguated record
Marco A. Passini
Also filed as: PASSINI MARCO · PASSINI MARCO A
25 granted patents·32 pending applications·171 citations·filing 2004–2025
96Inventor score
Top patents by PatentIndex Score
57 records- 0198US11911440B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2022·Granted Feb 27, 2024·5 cites·20 claims
- 0297US11975043B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2022·Granted May 7, 2024·3 cites·33 claims
- 0397US9717750B2Compositions and methods for modulation of SMN2 splicing in a subjectBIOGEN MA INC·Filed 2015·Granted Aug 1, 2017·26 cites·42 claims
- 0497US8980853B2Compositions and methods for modulation of SMN2 splicing in a subjectBENNETT C FRANK·Filed 2010·Granted Mar 17, 2015·48 cites·4 claims
- 0596US10369193B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2016·Granted Aug 6, 2019·17 cites·13 claims
- 0695US10888578B2Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2017·Granted Jan 12, 2021·6 cites·22 claims
- 0795US9415119B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2015·Granted Aug 16, 2016·13 cites·7 claims
- 0892US12350311B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2024·Granted Jul 8, 2025·0 cites·21 claims
- 0992US11253485B2Slow intraventricular deliveryGENZYME CORP·Filed 2019·Granted Feb 22, 2022·4 cites·15 claims
- 1091US10821154B2Compositions and methods for treating spinal muscular atrophyGENZYME CORP·Filed 2013·Granted Nov 3, 2020·7 cites·19 claims
- 1190US11000600B2Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2018·Granted May 11, 2021·6 cites·22 claims
- 1290US8926967B2Intraventricular enzyme delivery for lysosomal storage diseasesDODGE JAMES·Filed 2008·Granted Jan 6, 2015·13 cites·29 claims
- 1388US11395855B2Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2021·Granted Jul 26, 2022·1 cites·6 claims
- 1488US2024033323A1Gene Therapy For Neurodegenerative DisordersGENZYME CORP·Filed 2023·Application pending·0 cites
- 1588US2025288644A1Gene Therapy For Neurodegenerative DisordersGENZYME CORP·Filed 2025·Application pending·0 cites
- 1687US2024238326A1Compositions and methods for modulation of smn2 splicing in a subjectBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 1786US11338041B2Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2020·Granted May 24, 2022·1 cites·22 claims
- 1886US10765760B2Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2018·Granted Sep 8, 2020·1 cites·4 claims
- 1986US10080783B2Intraventricular enzyme delivery for lysosomal storage diseasesGENZYME CORP·Filed 2014·Granted Sep 25, 2018·6 cites·22 claims
- 2085US10744210B2Gene therapy for spinal cord disordersDODGE JAMES·Filed 2007·Granted Aug 18, 2020·8 cites·10 claims
- 2184US11382981B2Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2017·Granted Jul 12, 2022·3 cites·7 claims
- 2283US11957765B2Gene therapy for neurometabolic disordersGENZYME CORP·Filed 2020·Granted Apr 16, 2024·1 cites·9 claims
- 2382US2025064959A1Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2481US11642364B2Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2022·Granted May 9, 2023·0 cites·10 claims
- 2581US2023381216A1Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2680US2023110479A1Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2779US2025241940A1Modified antisense oligomers for exon inclusion in spinal muscular atrophySAREPTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2878US10905709B2Modified antisense oligomers for exon inclusion in spinal muscular atrophySAREPTA THERAPEUTICS INC·Filed 2016·Granted Feb 2, 2021·1 cites·11 claims
- 2977US12377150B2Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2022·Granted Aug 5, 2025·0 cites·18 claims
- 3077US2024000886A1Compositions and Methods for Treating Spinal Muscular AtrophyGENZYME CORP·Filed 2023·Application pending·0 cites
- 3177US2023287366A1Gene therapy for niemann-pick disease type aGENZYME CORP·Filed 2023·Application pending·0 cites
- 3275US2025090569A1Exon skipping oligomers and oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3375US2020376018A1Compositions and methods for modulation of smn2 splicing in a subjectBIOGEN MA INC·Filed 2019·Application pending·0 cites
- 3473US2020384076A1Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2020·Application pending·0 cites
- 3572US2021228692A1Intraventricular enzyme delivery for lysosomal storage diseasesGENZYME CORP·Filed 2020·Application pending·0 cites
- 3671US2022370348A1Slow intraventricular deliveryGENZYME CORP·Filed 2022·Application pending·0 cites
- 3770US12121532B2Modified antisense oligomers for exon inclusion in spinal muscular atrophySAREPTA THERAPEUTICS INC·Filed 2020·Granted Oct 22, 2024·0 cites·16 claims
- 3870US2021169919A1Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3969US10632213B2Gene therapy for neurometabolic disordersPASSINI MARCO A·Filed 2007·Granted Apr 28, 2020·1 cites·10 claims
- 4067US2025290069A1Exon skipping oligomers for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4166US2021121523A1Compositions and methods for treating spinal muscular atrophyGENZYME CORP·Filed 2020·Application pending·0 cites
- 4262US2019030058A1Compositions and methods for modulation of smn2 splicing in a subjectBIOGEN MA INC·Filed 2018·Application pending·0 cites
- 4362US2009123451A1Slow intraventricular deliveryGENZYME CORP·Filed 2008·Application pending·0 cites
- 4462US2021008227A1Gene therapy for spinal cord disordersGENZYME CORP·Filed 2020·Application pending·0 cites
- 4561US2021220386A1Exon skipping oligomers and oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4660US2009117156A1Gene therapy for niemann-pick disease type aGENZYME CORP·Filed 2008·Application pending·0 cites
- 4760US2019083582A1Intraventricular enzyme delivery for lysosomal storage diseasesGENZYME CORP·Filed 2018·Application pending·0 cites
- 4860US2004258666A1Gene therapy for neurometabolic disordersFiled 2004·Application pending·0 cites
- 4960US2022251551A1Exon skipping oligomers for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 5058US2020080066A1Gene therapy for niemann-pick disease type aGENZYME CORP·Filed 2019·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Marco A. Passini files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →